Drugs / EMB-09
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05263180 | Jul 2022 → Dec 2023 | neoplasm | Shanghai EpimAb Biotherapeutics Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMB-09 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05263180 ↗ |
| Route | Intravenous | “receive EMB-09 once a week (IV)” NCT05263180 ↗ |